PR Newswire
17 Jun 2022, 01:50 GMT+10
HONG KONG, June 17, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc. ("CLNK") recently announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application to initiate a Phase 1b, open-label study of CK0804 as an add on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib. Details related to this news can be found via the following Cellenkos news announcement:
Ms. Ting Zheng, Chief Executive Officer and Chairperson of GCBC commented, "The Global Cord Blood team is encouraged by the above news announced by CLNK which highlights a potentially transformative treatment for myelofibrosis patients. We congratulate CLNK team on this development."
About Global Cord Blood Corporation
Global Cord Blood Corporation is an umbilical cord blood banking operator serving multiple regions in China. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company's website at: http://www.globalcordbloodcorp.com.
For more information, please contact:
Global Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: [email protected]
ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: [email protected]
SOURCE Global Cord Blood Corporation
Get a daily dose of Singapore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Singapore Star.
More InformationAs Israeli tanks rolled into Gaza on Wednesday heralding a new ground invasion, a UN building was destroyed in a bombing, killing one...
WASHINGTON, D.C.: Johns Hopkins University announced this week that it will cut over 2,000 jobs in the U.S. and other countries. This...
LA MALBAIE, Canada: The United States will likely revoke visas of more students in the coming days, U.S. Secretary of State Marco Rubio...
WASHINGTON, D.C.: The U.S. government has placed more than 1,300 Voice of America (VOA) employees on leave and slashed funding for...
WASHINGTON, D.C./SEATTLE: Boeing is facing mounting scrutiny after a series of safety lapses and manufacturing issues, with U.S. Transportation...
OMAHA, Nebraska: Vaccines could help stop bird flu and prevent the mass killing of chickens, which has driven egg prices up to nearly...
SEATTLE/WASHINGTON D.C.: U.S. Transportation Secretary Sean Duffy said last week that the Federal Aviation Administration (FAA) is...
NEW YORK, New York - U.S. stocks rose Wednesday despite the U.S. Federal Reserve signalling a potential slowdown in the U.S. economy,...
WASHINGTON, D.C.: President Donald Trump has reversed a Biden-era executive order requiring businesses with federal contracts to pay...
FRANKFURT, Germany: UBS CEO Sergio Ermotti will receive a pay package of just over 15 million Swiss francs (US$17 million) for 2024,...
PARIS, France: French Prime Minister Francois Bayrou acknowledged over the weekend that the European Union may have miscalculated by...
NEW YORK, New York - Sellers took charge again on Wall Street Tuesday as the brief rebound that took place on Monday petered out. Stocks...